Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma DealsBenzinga • 05/07/25
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.The Motley Fool • 05/02/25
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and EnrollmentBusiness Wire • 05/01/25
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy SelectionBusiness Wire • 04/29/25
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation PlatformBusiness Wire • 04/28/25
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025Business Wire • 04/25/25
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?Zacks Investment Research • 04/24/25
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, PathosProactive Investors • 04/23/25
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in OncologyBusiness Wire • 04/23/25
Why Quantum Computing (QUBT), Nano Nuclear Energy (NNE) and Tempus AI (TEM) Are Popping Higher Today24/7 Wall Street • 04/22/25
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.Business Wire • 04/18/25
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovationPRNewsWire • 04/15/25
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?Zacks Investment Research • 04/11/25